Movement Alert｜Illumina Rises 5.16% in Regular Trading, RBC Sees Clinical Sequencing Momentum and Fading Competition

Market Focus08-19 21:40

On August 19, Illumina rose 5.16% in regular trading, reaching $198.835 per share with turnover of approximately $47.14 million.

On the news front, RBC Capital Markets issued a report highlighting that Illumina is building strong clinical sequencing momentum while competitive concerns surrounding the company are fading. RBC projects clinical sequencing revenue can grow at a durable mid-teens rate, driven by oncology testing volume growth and easing pricing headwinds. While sequencing instrument sales could face double-digit declines in 2027, clinical sequencing and services are expected to offset this weakness. RBC maintains an Outperform rating with a $230 price target, raised from $170 in late July following Q2 results that beat estimates with adjusted EPS of $1.31 versus $1.23 expected and revenue of $1.159 billion versus $1.130 billion estimated.

The broader Life Sciences Tools and Services sector also rallied, with Tempus AI up 11.43%, Repligen up 6.07%, and Danaher up 4.09%, providing additional sector-wide support.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166724932?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-19 21:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166724932","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Illumina Rises 5.16% in Regular Trading, RBC Sees Clinical Sequencing Momentum and Fading Competition","media":"Market Focus","content":"<p><p>On August 19, Illumina rose 5.16% in regular trading, reaching $198.835 per share with turnover of approximately $47.14 million.</p><p>On the news front, RBC Capital Markets issued a report highlighting that Illumina is building strong clinical sequencing momentum while competitive concerns surrounding the company are fading. RBC projects clinical sequencing revenue can grow at a durable mid-teens rate, driven by oncology testing volume growth and easing pricing headwinds. While sequencing instrument sales could face double-digit declines in 2027, clinical sequencing and services are expected to offset this weakness. RBC maintains an Outperform rating with a $230 price target, raised from $170 in late July following Q2 results that beat estimates with adjusted EPS of $1.31 versus $1.23 expected and revenue of $1.159 billion versus $1.130 billion estimated.</p><p>The broader Life Sciences Tools and Services sector also rallied, with Tempus AI up 11.43%, Repligen up 6.07%, and Danaher up 4.09%, providing additional sector-wide support.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Illumina Rises 5.16% in Regular Trading, RBC Sees Clinical Sequencing Momentum and Fading Competition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Illumina Rises 5.16% in Regular Trading, RBC Sees Clinical Sequencing Momentum and Fading Competition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-19 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 19, Illumina rose 5.16% in regular trading, reaching $198.835 per share with turnover of approximately $47.14 million.</p><p>On the news front, RBC Capital Markets issued a report highlighting that Illumina is building strong clinical sequencing momentum while competitive concerns surrounding the company are fading. RBC projects clinical sequencing revenue can grow at a durable mid-teens rate, driven by oncology testing volume growth and easing pricing headwinds. While sequencing instrument sales could face double-digit declines in 2027, clinical sequencing and services are expected to offset this weakness. RBC maintains an Outperform rating with a $230 price target, raised from $170 in late July following Q2 results that beat estimates with adjusted EPS of $1.31 versus $1.23 expected and revenue of $1.159 billion versus $1.130 billion estimated.</p><p>The broader Life Sciences Tools and Services sector also rallied, with Tempus AI up 11.43%, Repligen up 6.07%, and Danaher up 4.09%, providing additional sector-wide support.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILMN","symbol_name":"Illumina","start_time":0,"source_url":"","article_id":"1166724932","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166724932","pubTimestamp":1787146827,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 19, Illumina rose 5.16% in regular trading, reaching $198.835 per share with turnover of approximately $47.14 million.On the news front, RBC Capital Markets issued a report highlighting...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ILMN":"Illumina"},"translate_title":"动态警报|Illumina 常规交易上涨 5.16%，RBC 看到临床测序势头强劲，竞争减弱","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":1},"content_text":"On August 19, Illumina rose 5.16% in regular trading, reaching $198.835 per share with turnover of approximately $47.14 million.On the news front, RBC Capital Markets issued a report highlighting that Illumina is building strong clinical sequencing momentum while competitive concerns surrounding the company are fading. RBC projects clinical sequencing revenue can grow at a durable mid-teens rate, driven by oncology testing volume growth and easing pricing headwinds. While sequencing instrument sales could face double-digit declines in 2027, clinical sequencing and services are expected to offset this weakness. RBC maintains an Outperform rating with a $230 price target, raised from $170 in late July following Q2 results that beat estimates with adjusted EPS of $1.31 versus $1.23 expected and revenue of $1.159 billion versus $1.130 billion estimated.The broader Life Sciences Tools and Services sector also rallied, with Tempus AI up 11.43%, Repligen up 6.07%, and Danaher up 4.09%, providing additional sector-wide support.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166724932","isCrawlerRequest":true}